Heart-racing? NASCAR picks cardiovascular partner
Candace Stuart | March 25, 2014 | Cardiovascular Business | Vascular & Endovascular

Ladies and gentlemen, start your rrr, rrr, rrr-rivaroxaban? NASCAR, the auto racing aficionado organization, announced that Janssen Pharmaceuticals has become its official cardiovascular partner.

Janssen, maker of the anticoagulant rivaroxaban (Xarelto), is partnering with NASCAR on promotions that include prominent race car driver Brian Vickers. Vickers shares his experience with treatment after episodes of deep vein thrombosis, which temporarily sidelined his racing career. Rivaroxaban has been approved by the FDA to treat deep vein thrombosis or pulmonary embolism and to reduce the risk of recurrent deep vein thrombosis and pulmonary embolism following initial treatment.

Jannsen co-sponsored a custom “TreatMyClot.com” Toyota Camry in a recent race that coincided with National Blood Clot Awareness Month. Vickers placed seventh, according to his website, which advances him in overall points and may secure a placement in upcoming races.

Candace Stuart, Contributor

Related Content

Boston Scientific recalls premixed embolic agent after two deaths
Anemia may help explain why women are more likely to die during heart bypass surgery
FDA grants anticoagulant its orphan drug designation for treating patients with implanted devices
FDA announces new recall of neurovascular catheters built by Johnson & Johnson subsidiary
GE Healthcare launching new AI software for handheld ultrasound system
New study provides ‘substantial evidence’ paclitaxel-coated devices are safe when treating lower-limb PAD

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Radiology Business
Philips launches new AI-enabled CT scanner aimed at cardiology at ECR 2024

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Design by Adaptive Theme
Trimed Popup
Trimed Popup